Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Sagar S. Patel(University of Utah), Avyakta Kallam(City Of Hope National Medical Center), David Bernasconi(Bristol-Myers Squibb (United States)), Matthew J. Frigault(Harvard University), Bradley D. Hunter(Intermountain Healthcare), Marcelo C. Pasquini(Cleveland Clinic), Soyoung Kim(Medical College of Wisconsin), Fei‐Fei Liu(Jiangsu Hengrui Medicine (China)), Debasmita Roy(Bristol-Myers Squibb (United States)), Tracy Krimmel(Bristol-Myers Squibb (United States))
Cited by 6
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484